Table 1. Baseline patient characteristics.
| n % | |
|---|---|
| All | 20 |
| Age, mean (SD) | 61 (9.6) |
| Women | 5 (25) |
| Cancer diagnosis | |
| Lung cancer | 6 (30) |
| Renal cell carcinoma | 5 (25) |
| Melanoma | 3 (15) |
| Other | 6 (30) |
| Prior Therapy | |
| Anthracycline | 1 (5) |
| Monoclonal antibody (trastuzumab, bevacizumab) | 4 (20) |
| Alkylating agent | 4 (20) |
| Protein kinase inhibitor | 3 (15) |
| Taxol | 5 (25) |
| 5-flurouracil | 1 (5) |
| Carboplatin | 4 (20) |
| Other | 8 (40) |
| Immune checkpoint inhibitor | 3 (15) |
| Thoracic Radiotherapy | 4 (20) |
| Checkpoint inhibitor at time of presentation | |
| Atezolizumab | 1 (6) |
| Pembrolizumab | 6 (35) |
| Ipilimumab | 6 (35) |
| Nivolumab | 9 (53) |
| Durvalumab | 2 (12) |
| Tremelimumab | 2 (12) |
| Dual immune checkpoint inhibitors | 6 (30) |
| Past Medical History and Current Medications | |
| Tobacco use | 11 (55) |
| Hypertension | 8 (40) |
| Myocardial infarction | 2 (10) |
| Arrhythmia | 3 (15) |
| Diabetes | 6 (30) |
| CVA (TIA or stroke) | 2 (10) |
| Hyperlipidemia | 5 (25) |
| Coronary artery disease | 3 (15) |
| PCI (percutaneous coronary intervention) | 2 (10) |
| Beta Blocker | 7 (35) |
| ACE-inhibitor/Angiotensin Receptor Blocker | 6 (30) |
| Calcium Channel Blocker | 5 (25) |
| Statin | 7 (35) |
| Aspirin | 6 (30) |
| Direct Oral Anticoagulant | 4 (20) |
| Insulin | 4 (20) |
| Oral diabetes medication | 2 (10) |
| Labs | |
| Peak troponin T ng/mL, mean (SD) (reference range < .01 ng/mL) | 1.2 (3.2) |
| B-type natriuretic peptide pg/mL, mean (SD) (reference range < 450 pg/mL) | 5751 (9177) |
| Creatinine mg/dL, mean (SD) | 1.2 (0.9) |
| Concomitant immune checkpoint inhibitor related adverse events | |
| Pneumonitis | 3 (15) |
| Thyroiditis | 3 (15) |
| Myositis | 2 (10) |
| Colitis | 1 (5) |
| Diabetes | 1 (5) |